News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oriel Therapeutics Inc. Signs Development And Licensing Agreement; New Agreement To Allow Development Of Novel Cystic Fibrosis Treatment


10/19/2005 5:09:18 PM

Oriel Therapeutics, an emerging inhaled drug delivery company, today announced that it has signed a development and licensing agreement with an undisclosed U.S.-based biotechnology company to develop a novel therapy for the treatment of cystic fibrosis. This therapy will be based on Oriel Therapeutics' proprietary dry powder inhalation technology incorporating the partner's proprietary compounds that represent a novel mode of action to improve airway function.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES